Paper Review Records
All Paper Review Records
21 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
70
days
Cost-effectiveness analysis of pneumococcal vaccination of at-risk and high-risk adults aged 18–64 years in Switzerland using PCV21
Authors
Muloongo Simuzingili; Zinan Yi; Andrea Favre-Bulle; Thomas Mutschler; Eleana Tsoumani; Kwame Owusu-EduseiShow moreShow less
Affiliations
1. Merck & Co., Inc; 2. MSD Switzerland; 3. MSD GreeceShow moreShow less
114
days
Projected burden of bloodstream infections and the impact of molecular rapid diagnostic testing on costs and mortality in England and the United States (2025–2029): a population-level budget impact analysis
Authors
James K. Karichu; Mark Pennington; Kiera Lander; Tiffeny T. Smith; Adam ThornbergShow moreShow less
Affiliations
1. Roche Molecular Systems; 2. Source Health Economics; 3. Roche Diagnostics CorporationShow moreShow less
62
days
Societal and fiscal gains from HPV vaccination in Poland – return on investment from extending access to HPV vaccination
Authors
Rafal Jaworski; Nikolaos Kotsopoulos; Marcin Czech; Mark P. Connolly; Andrew Pavelyev; Alicja Wojcik; Ugne SabaleShow moreShow less
Affiliations
1. Market Access Department, MSD; 2. Global Market Access Solutions Sàrl; 3. University of Athens; 4. Pharmacoeconomic Department, Institute of Mother and Child; 5. University Groningen; 6. Health Economic and Decision Sciences, Merck & Co., Inc; 7. Value & Implementation Outcomes Research, MSD VilniusShow moreShow less
41
days
Cost-effectiveness analysis of elranatamab versus physician’s choice of treatment (non–BCMA-directed regimens) in patients with triple class exposed multiple myeloma in Japan
Authors
Akira Yuasa; Mitsuhiro Nagano; Yoichi Kamei; Kengo Hatsuyama; Hiroyuki Matsuda; Patrick Hlavacek; Marco DiBonaventura; Kenshi SuzukiShow moreShow less
Affiliations
1. Japan Access & Value, Pfizer Japan Inc; 2. Pfizer R&D Japan G.K; 3. Real World Evidence Solutions & HEOR, IQVIA Solutions Japan G.K; 4. HTA, Value & Evidence, Pfizer Inc; 5. Myeloma/AL Amyloid Unit, Japanese Red Cross Medical CenterShow moreShow less
42
days
Real-world healthcare resource utilization and cost burden of COVID-19 in commercially insured adults at high-risk of severe disease in the US: a retrospective database analysis
Authors
Tendai Mugwagwa; Benjamin A. Abramoff; Siddharth Karanth; Tram Nham; Ravi K. Goyal; Elizabeth Esterberg; Gurinder S. Sidhu; Alon Yehoshua; Ruth MokgokongShow moreShow less
Affiliations
1. Pfizer Ltd; 2. University of Pennsylvania; 3. RTI Health Solutions; 4. Pfizer IncShow moreShow less
53
days
Cost-effectiveness analysis of Cardioform vs. Amplatzer: concerns regarding methodological transparency and interpretation of clinical results
Authors
David W. Hutton; Anne M. Ryschon; Scott Goates; Jan B. Pietzsch; Lars SøndergaardShow moreShow less
Affiliations
1. Department of Health Management and Policy, University of Michigan; 2. Wing Tech Inc; 3. Global Data Science and Analysis; 4. Abbott, CA, USAShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
